AIM/HYPOTHESIS: Studies investigating the structure, neurophysiology and functional outcomes of white matter among type 1 diabetes patients have given conflicting results. Our aim was to investigate the relationship between type 1 diabetes and white matter hyperintensities. METHOD: We assessed white matter integrity (using magnetic resonance imaging), depressive symptoms and neuropsychological function in 114 type 1 diabetes patients and 58 age-matched non-diabetic controls. RESULTS: Only Fazekas grade 1 and 2 white matter hyperintensities were found among 114 long-duration, relatively young diabetes patients; the severity of lesions did not differ substantially from 58 healthy controls. White matter hyperintensities were not associated with depressive history or with clinical characteristics of diabetes, including retinopathy, severe hypoglycaemia or glycaemia control. CONCLUSIONS/ INTERPRETATION: Our data do not support an association between diabetes characteristics and white matter hyperintensities among relatively young type 1 diabetes participants.
AIM/HYPOTHESIS: Studies investigating the structure, neurophysiology and functional outcomes of white matter among type 1 diabetespatients have given conflicting results. Our aim was to investigate the relationship between type 1 diabetes and white matter hyperintensities. METHOD: We assessed white matter integrity (using magnetic resonance imaging), depressive symptoms and neuropsychological function in 114 type 1 diabetespatients and 58 age-matched non-diabetic controls. RESULTS: Only Fazekas grade 1 and 2 white matter hyperintensities were found among 114 long-duration, relatively young diabetespatients; the severity of lesions did not differ substantially from 58 healthy controls. White matter hyperintensities were not associated with depressive history or with clinical characteristics of diabetes, including retinopathy, severe hypoglycaemia or glycaemia control. CONCLUSIONS/ INTERPRETATION: Our data do not support an association between diabetes characteristics and white matter hyperintensities among relatively young type 1 diabetesparticipants.
Authors: J B Williams; M Gibbon; M B First; R L Spitzer; M Davies; J Borus; M J Howes; J Kane; H G Pope; B Rounsaville Journal: Arch Gen Psychiatry Date: 1992-08
Authors: P B Moore; D J Shepherd; D Eccleston; I C Macmillan; U Goswami; V L McAllister; I N Ferrier Journal: Br J Psychiatry Date: 2001-02 Impact factor: 9.319
Authors: Gail Musen; In Kyoon Lyoo; Caitlin R Sparks; Katie Weinger; Jaeuk Hwang; Christopher M Ryan; David C Jimerson; John Hennen; Perry F Renshaw; Alan M Jacobson Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: R Schmidt; F Fazekas; H Offenbacher; T Dusek; E Zach; B Reinhart; P Grieshofer; W Freidl; B Eber; M Schumacher Journal: Neurology Date: 1993-12 Impact factor: 9.910
Authors: Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw Journal: Arch Gen Psychiatry Date: 2004-05
Authors: Christopher T Kodl; Daniel T Franc; Jyothi P Rao; Fiona S Anderson; William Thomas; Bryon A Mueller; Kelvin O Lim; Elizabeth R Seaquist Journal: Diabetes Date: 2008-08-11 Impact factor: 9.461
Authors: Karen A Nunley; Christopher M Ryan; Trevor J Orchard; Howard J Aizenstein; J Richard Jennings; John Ryan; Janice C Zgibor; Robert M Boudreau; Tina Costacou; John D Maynard; Rachel G Miller; Caterina Rosano Journal: Neurology Date: 2015-04-22 Impact factor: 9.910
Authors: Hazel Mae A Abraham; Leslie Wolfson; Nicola Moscufo; Charles R G Guttmann; Richard F Kaplan; William B White Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Sujung Yoon; Jungyoon Kim; Gail Musen; Perry F Renshaw; Jaeuk Hwang; Nicolas R Bolo; Jieun E Kim; Donald C Simonson; Katie Weinger; Christopher M Ryan; In Kyoon Lyoo; Alan M Jacobson Journal: Pediatr Diabetes Date: 2017-09-20 Impact factor: 4.866